Cingulate

Cingulate Capital Intensity

Capital Intensity Ratio of Cingulate (CING) as of Oct 18, 2026.

Capital Intensity

-

Last updated:

Capital Intensity Ratio of Cingulate is 2026 - . Capital Intensity Ratio of Cingulate was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc, headquartered in Kansas City, Kansas, is a US-based biopharmaceutical company operating in the Pharmaceuticals sector. The company focuses on developing and commercializing pharmaceutical products using its precision timed release (PTR) drug delivery platform, specifically targeting attention deficit/hyperactivity disorder (ADHD). Cingulate is developing two lead product candidates, CTx-1301 and CTx-1302, designed as single-tablet formulations with three release phases for children, adolescents, and adults with ADHD. The company, listed on October 7, 2021, employs 15 full-time staff. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Cingulate since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Cingulate with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Cingulate

All Key Metrics — Cingulate